Novo Nordisk A/S

(New York Stock Exchange)
Back to all articles
Somewhat Bearish -25

Novo Nordisk’s Growth Story Is Under Pressure as Eli Lilly Gains Ground

Company update Financial outlook AI-generated analysis

📉 Novo Nordisk stock declined over 25% since early 2026, trading at 11.83x forward earnings as investors price in competitive and pricing pressures.

💊 The company launched the oral Wegovy pill in January 2026, with total prescriptions surpassing three million by June 2026.

📈 Novo reported 2025 sales of DKK 309 billion with obesity-care sales reaching DKK 82 billion and continued GLP-1 volume growth.

⚔️ Eli Lilly is gaining significant ground, with Mounjaro sales jumping 91% to $9.94 billion in Q2 2026 while Novo's Wegovy pill generated $497 million.

📉 Management raised its 2026 adjusted sales outlook in August, but the new guidance still calls for 0% to -6% growth at constant exchange rates.

🧬 CagriSema remains a critical pipeline opportunity, showing superior weight loss to tirzepatide in the REIMAGINE 5 trial and 21% weight loss versus placebo.

🎯 Novo Nordisk aims to launch more than five multi-blockbuster medicines by 2030 and generate over DKK 150 billion in pipeline sales by 2035.

⚠️ The company faces credible competition, increasing pricing pressure, and a challenging outlook that prevents it from being treated as an obvious bargain.

Bullish Signals
  • Novo Nordisk launched the oral Wegovy pill in January 2026, with total prescriptions surpassing three million by June, demonstrating successful expansion into new dosage forms.
  • The company reported 2025 sales of DKK 309 billion with a compound annual growth rate of 17%, maintaining one of the world's largest positions in obesity and diabetes care.
  • CagriSema produced superior weight loss to tirzepatide in the REIMAGINE 5 trial, showing 21% weight loss versus placebo in adults with overweight or obesity.
  • Management aims to launch more than five multi-blockbuster medicines by 2030, providing a credible route back to growth beyond current franchises.
Risk Factors
  • Novo Nordisk faces stronger competition from Eli Lilly, with Lilly's Mounjaro sales jumping 91% to $9.94 billion in Q2 2026 while Novo's Wegovy pill generated only $497 million.
  • The company is experiencing pricing pressure in the U.S. market and slower-than-expected momentum from its new oral semaglutide product, Wegovy.
  • Management raised its 2026 outlook but guidance still projects 0% to -6% growth at constant exchange rates, indicating a decline in adjusted sales and operating profit.
  • The investment case now depends on whether current problems represent a temporary reset or a fundamental change in Novo's long-term growth trajectory.
Full Analysis
Novo Nordisk's (NYSE:NVO) investment narrative has shifted significantly as the stock declined over 25% since early 2026, settling at a forward P/E of 11.83x compared to 13.33x in September 2025. This valuation compression reflects growing competitive pressures from Eli Lilly, pricing challenges in the U.S., and slower-than-anticipated momentum for its new oral semaglutide product, Wegovy. Despite these headwinds, Novo maintains a substantial franchise with 2025 sales reaching DKK 309 billion and obesity-care sales climbing to DKK 82 billion. The company successfully launched the Wegovy pill in January 2026, surpassing three million prescriptions by June, and introduced a higher-dose 7.2 mg formulation to expand its addressable market beyond injectables. However, Novo faces a difficult environment where first-mover advantage is no longer sufficient against Eli Lilly's strong Mounjaro and Zepbound sales. While management raised its 2026 outlook in August, the guidance still projects 0% to -6% growth at constant exchange rates, driven by GLP-1 volume rather than a return to high growth rates. The company's future hinges on its pipeline, specifically CagriSema which showed superior weight loss results in recent trials, and ambitions to launch five multi-blockbuster medicines by 2030. Investors must determine if the current valuation represents a temporary reset or a fundamental change in Novo's growth trajectory amidst credible competition.